Dermira
ClosedBringing biotech ingenuity to medical dermatology
- Headquarters
- Menlo Park, California
- Employees
- 201–500
- Founded
- 2010
- Business Model
- B2B
- Website
- dermira.com
- Total Funding
- $202.0M
- Last Round
- $125.0M Venture RoundOct 2014
- Rounds
- 5
About
Dermira was a specialty biopharmaceutical company dedicated to developing differentiated therapies for chronic skin conditions. Based in Menlo Park, California, Dermira developed lebrikizumab (an IL-13 antibody for atopic dermatitis) and Qbrexza (for hyperhidrosis). The company was acquired by Eli Lilly for approximately $1.1 billion in 2020.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...